Mel C. O'leary

West Lakes Science And Technology Park
Moor Row, ENG CA243HA, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A new approach for simulating inhomogeneous chemical kinetics.

A new approach for simulating inhomogeneous chemical kinetics.

Journal: Scientific reports

Published: March 29, 2023

A new approach for simulating inhomogeneous chemical kinetics.

A new approach for simulating inhomogeneous chemical kinetics.

Journal: Scientific reports

Published: March 29, 2023

COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.

COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest.

Journal: Public health

Published: February 08, 2023

First observation of radiolytic bubble formation in unstirred nano-powder sludges and a consistent model thereof.

First observation of radiolytic bubble formation in unstirred nano-powder sludges and a consistent model thereof.

Journal: Scientific reports

Published: July 13, 2021

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.

Journal: Nature medicine

Published: May 04, 2021

Observation of dose-rate dependence in a Fricke dosimeter irradiated at low dose rates with monoenergetic X-rays.

Observation of dose-rate dependence in a Fricke dosimeter irradiated at low dose rates with monoenergetic X-rays.

Journal: Scientific reports

Published: August 16, 2017

Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK.

Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients.

Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 01, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026